What we do
Three things, done in-house.
01
Identifying Opportunities
Continuous screening of EU MA registries, industry intelligence, and direct relationships with divestors. We find products before they hit the open market.
02
Due Diligence
Full regulatory gap analysis: MA status per market, CMC data integrity, pharmacovigilance obligations, supply chain dependencies, patent and SPC landscape.
03
Transfer Execution
We manage the MA transfer with each national authority simultaneously. Type II variations, QPPV changes, labelling updates — all coordinated from one project team.
Why it matters
Every product we acquire would otherwise risk discontinuation. Acquisition is the first link in the chain — without it, no regulatory management, no supply continuity, no patient access.
One link in the chain. No gaps.
Related capabilities